143 related articles for article (PubMed ID: 29260621)
41. Antibodies against the C-terminus of α-synuclein modulate its fibrillation.
Sahin C; Lorenzen N; Lemminger L; Christiansen G; Møller IM; Vesterager LB; Pedersen LØ; Fog K; Kallunki P; Otzen DE
Biophys Chem; 2017 Jan; 220():34-41. PubMed ID: 27863716
[TBL] [Abstract][Full Text] [Related]
42. Can α-synuclein be targeted in novel therapies for Parkinson's disease?
Brundin P; Olsson R
Expert Rev Neurother; 2011 Jul; 11(7):917-9. PubMed ID: 21721907
[No Abstract] [Full Text] [Related]
43. Parkinson's disease: Autoimmunity and neuroinflammation.
De Virgilio A; Greco A; Fabbrini G; Inghilleri M; Rizzo MI; Gallo A; Conte M; Rosato C; Ciniglio Appiani M; de Vincentiis M
Autoimmun Rev; 2016 Oct; 15(10):1005-11. PubMed ID: 27497913
[TBL] [Abstract][Full Text] [Related]
44. Investigational α-synuclein aggregation inhibitors: hope for Parkinson's disease.
Török N; Majláth Z; Szalárdy L; Vécsei L
Expert Opin Investig Drugs; 2016 Nov; 25(11):1281-1294. PubMed ID: 27677932
[TBL] [Abstract][Full Text] [Related]
45. Structural Effects of Two Camelid Nanobodies Directed to Distinct C-Terminal Epitopes on α-Synuclein.
El-Turk F; Newby FN; De Genst E; Guilliams T; Sprules T; Mittermaier A; Dobson CM; Vendruscolo M
Biochemistry; 2016 Jun; 55(22):3116-22. PubMed ID: 27096466
[TBL] [Abstract][Full Text] [Related]
46. Autosomal dominant Parkinson's disease and the route to new therapies.
Morris HR
Expert Rev Neurother; 2007 Jun; 7(6):649-56. PubMed ID: 17563248
[TBL] [Abstract][Full Text] [Related]
47. Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders.
Neff F; Wei X; Nölker C; Bacher M; Du Y; Dodel R
Autoimmun Rev; 2008 Jun; 7(6):501-7. PubMed ID: 18558370
[TBL] [Abstract][Full Text] [Related]
48. Alpha-synuclein, Parkinson's disease, and Alzheimer's disease.
Kim S; Seo JH; Suh YH
Parkinsonism Relat Disord; 2004 May; 10 Suppl 1():S9-13. PubMed ID: 15109581
[TBL] [Abstract][Full Text] [Related]
49. Parkinson disease and the immune system - associations, mechanisms and therapeutics.
Tan EK; Chao YX; West A; Chan LL; Poewe W; Jankovic J
Nat Rev Neurol; 2020 Jun; 16(6):303-318. PubMed ID: 32332985
[TBL] [Abstract][Full Text] [Related]
50. Fine epitope mapping of monoclonal antibodies specific to human alpha-synuclein.
Choi JY; Park HJ; Seong YM; Choi EY; Min BR; Rhim H
Neurosci Lett; 2006 Apr 10-17; 397(1-2):53-8. PubMed ID: 16380207
[TBL] [Abstract][Full Text] [Related]
51. Naturally occurring alpha-synuclein autoantibodies in Parkinson's disease: sources of (error) variance in biomarker assays.
Heinzel S; Gold M; Deuschle C; Bernhard F; Maetzler W; Berg D; Dodel R
PLoS One; 2014; 9(12):e114566. PubMed ID: 25470145
[TBL] [Abstract][Full Text] [Related]
52. Antibody-mediated immunotherapy against chronic hepatitis B virus infection.
Gao Y; Zhang TY; Yuan Q; Xia NS
Hum Vaccin Immunother; 2017 Aug; 13(8):1768-1773. PubMed ID: 28521640
[TBL] [Abstract][Full Text] [Related]
53. Therapeutic strategies for Parkinson's disease based on data derived from genetic research.
Riess O; Berg D; Krüger R; Schulz JB
J Neurol; 2003 Feb; 250 Suppl 1():I3-10. PubMed ID: 12761628
[TBL] [Abstract][Full Text] [Related]
54. Immunoprotection against toxic biomarkers is retained during Parkinson's disease progression.
Gruden MA; Sewell RD; Yanamandra K; Davidova TV; Kucheryanu VG; Bocharov EV; Bocharova OA; Polyschuk VV; Sherstnev VV; Morozova-Roche LA
J Neuroimmunol; 2011 Apr; 233(1-2):221-7. PubMed ID: 21239064
[TBL] [Abstract][Full Text] [Related]
55. Aggregation-defective alpha-synuclein mutants inhibit the fibrillation of Parkinson's disease-linked alpha-synuclein variants.
Koo HJ; Choi MY; Im H
Biochem Biophys Res Commun; 2009 Aug; 386(1):165-9. PubMed ID: 19501571
[TBL] [Abstract][Full Text] [Related]
56. α-Synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson's disease.
Lastres-Becker I; Ulusoy A; Innamorato NG; Sahin G; Rábano A; Kirik D; Cuadrado A
Hum Mol Genet; 2012 Jul; 21(14):3173-92. PubMed ID: 22513881
[TBL] [Abstract][Full Text] [Related]
57. The Anti-Amyloid-β Monoclonal Antibody 4G8 Recognizes a Generic Sequence-Independent Epitope Associated with α-Synuclein and Islet Amyloid Polypeptide Amyloid Fibrils.
Hatami A; Monjazeb S; Glabe C
J Alzheimers Dis; 2016; 50(2):517-25. PubMed ID: 26682688
[TBL] [Abstract][Full Text] [Related]
58. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease.
Masliah E; Rockenstein E; Adame A; Alford M; Crews L; Hashimoto M; Seubert P; Lee M; Goldstein J; Chilcote T; Games D; Schenk D
Neuron; 2005 Jun; 46(6):857-68. PubMed ID: 15953415
[TBL] [Abstract][Full Text] [Related]
59. An antibody with high reactivity for disease-associated α-synuclein reveals extensive brain pathology.
Kovacs GG; Wagner U; Dumont B; Pikkarainen M; Osman AA; Streichenberger N; Leisser I; Verchère J; Baron T; Alafuzoff I; Budka H; Perret-Liaudet A; Lachmann I
Acta Neuropathol; 2012 Jul; 124(1):37-50. PubMed ID: 22370907
[TBL] [Abstract][Full Text] [Related]
60. Biotherapies in brain diseases: for who, when and how?
Remy P
Rev Neurol (Paris); 2014 Dec; 170(12):725-6. PubMed ID: 25459123
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
